fascaplysine has been researched along with Cancer of Ovary in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, S; Guan, X; Li, B; Liu, Y; Sang, XB; Wang, LL; Zhao, Y | 1 |
| Boyd, MR; Charan, RD; McKee, TC | 1 |
2 other study(ies) available for fascaplysine and Cancer of Ovary
| Article | Year |
|---|---|
Fascaplysin inhibit ovarian cancer cell proliferation and metastasis through inhibiting CDK4.
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase 4; Female; Gene Expression Regulation, Neoplastic; Humans; Indoles; Neoplasm Invasiveness; Neoplasm Metastasis; Ovarian Neoplasms; Proto-Oncogene Proteins c-bcl-2; Vascular Endothelial Growth Factor A | 2017 |
Cytotoxic alkaloids from the marine sponge Thorectandra sp.
Topics: Animals; Breast Neoplasms; Cell Division; Drug Screening Assays, Antitumor; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Indoles; Ovarian Neoplasms; Porifera; Tumor Cells, Cultured | 2004 |